Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases
About usBetter understanding of complex disease biology
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people
Accurately defining sub-groups of patients enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient
New disease insights through collaboration
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes
Why PrecisionLife?
Our unique combinatorial analytics platform unpicks the complex causes of disease and delivers a high-resolution patient stratification based on deep insights into novel target biology.
We bring together data, technology, industry experts and collaborative partners to transform our understanding of chronic disease and find new therapy options for patients.
PrecisionLife’s platform provides detailed contextual information on the SNPs, genes and pathways driving disease in patient sub-groups, and their active chemistry, tissue expression, mechanism of action, IP, clinical trials and more.
Pharma & Biotech
Selecting the right disease biology and drug target is crucial to innovative drug discovery
Clinical Development
Recruiting the right patients is critical to demonstrating efficacy and running smaller, faster and more successful clinical trials
Healthcare
Understanding the personal factors influencing chronic disease risk, progression rate and treatment response is vital to improved care
Latest Disease Studies
Read all Disease StudiesLatest News & Media
View all
News
Publications
Events
PrecisionLife unveils new spin-out Synomics taking its proven analytics platform into animal and crop health sectors
OXFORD, UK, April 7, 2021 PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out…
7/04/21
PrecisionLife continues growth and expansion with acquisition of Danish genomic analytics innovator GenoKey
OXFORD, UK, and AALBORG, Denmark, March 24, 2021 PrecisionLife today announces that it has acquired its long-term Danish technology…
24/03/21
PrecisionLife joins Nvidia Inception – the premier program for AI and data science startups
PrecisionLife will benefit from Nvidia’s Inception program that supports AI companies from “seed to unicorn” status providing the company…
15/03/21
PrecisionLife Pharma and Biotech BD team to attend Bio-Europe Spring
It is the “must-attend” event that has gone digital and PrecisionLife will be represented by its new Business Development…
15/03/21
Digital Medicine and Preventative Healthcare Precision Medicine vs Wearable
Digital Medicine and Preventative Healthcare Precision Medicine vs Wearable – Online Event
13/02/21
One Nucleus – BioWednesday Webinar – Feb 3, 2021
Oxford, UK – PrecisionLife CEO Dr Steve Gardner will be chairing a discussion at this event, organised by One…
27/01/21
Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients
A study using de-identified clinical claims and labs data for US COVID-19 patients. We replicated previous findings around the…
25/02/21
The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization
The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a…
26/09/20AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies
Access to huge patient populations with well-characterized datasets, coupled with novel analytical methods, enables the stratification of complex diseases…
26/06/20